Thermo Fisher Scientific CD11a Monoclonal Antibody (121/7)

Applications

Tested Dilution

Publications

Western Blot (WB)

-

View 1 publication 1 publication

Flow Cytometry (Flow)

Assay-dependent

-

Immunoprecipitation (IP)

-

View 1 publication 1 publication

Neutralization (Neu)

Assay-dependent

View 1 publication 1 publication

Inhibition Assays (IA)

Assay-dependent

-

Product Specifications

Species Reactivity

Mouse

Published species

Mouse

Host/Isotype

Rat / IgG2a

Class

Monoclonal

Type

Antibody

Clone

121/7

Immunogen

Mouse 180kD alpha chain (CD11alpha) of the integrin Lymphocyte Function-Associated Antigen-1

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Protein G

Storage buffer

PBS

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_223586

Product Specific Information

MA11A5 targets CD11a in FACS, IA, and Neu applications and shows reactivity with mouse samples. This antibody does not react with human Jurkat cells in FACS applications.

The MA11A5 immunogen is mouse 180kD alpha chain (CD11alpha) of the integrin Lymphocyte Function-Associated Antigen-1.

MA11A5 detects CD11a which has a predicted molecular weight of approximately 126 kDa.

This antibody is produced by injecting Rat IgG secreting hybridoma cells into the peritoneum of mice. The resulting ascites is collected from the mice and the antibody is purified.

This product is a Low Endotoxin formulation.

This product has been tested for endotoxins by limulus amoebocyte lysate (LAL) assay and contains an endotoxin concentration of less than or equal to 10 endotoxin units per milligram (EU/mg).

Target Information

CD11a (LFA-1 alpha, ITGAL) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin. CD11a is implicated in activation of LFA-1 complex. CD11a plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling. CD11a is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of CD11a to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. CD11a is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of CD11a function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti- CD11a antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation, binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity. Two transcript variants encoding different isoforms of CD11a have been found. Diseases associated with CD11a dysfunction include benign cephalic histiocytosis and leukocyte adhesion deficiency.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.